Is there any data to support radiation and targeted agents (Braf inhibitor or ipilimumab) combined for stage III melanoma?

Prospective trials will be reported this year at ASCO on the role of adjuvant ipilimumab (an immunotherapeutic, not a targeted therapy) for melanoma. Prospective trials of adjuvant BRAF inhibitors (vemurafenib, and others) for melanoma are ongoing (not yet reported). At present (4/25/14), there is n...